Onco Actu du 6 novembre 2015

	2.11 Etiologie - Alimentation
Red meat makes a good, scary cancer story....but is it? [The Mermaid's Tale] This is a lesson in complex causation and oversimplified news stories. Processed meat may be a risk factor for colon cancer, but throwing irresponsibly simplified figures like raw meat to the news media leads to worse, rather than better information for the public.
Know your risks, but meat still isn’t the enemy [The Incidental Economist] If you’re consuming multiple portions of processed meat a day, then you may see some small benefit in the lifetime risk of cancer by cutting back. But if you’re like most people I know, enjoying bacon or prosciutto a couple of times a week, this news most likely doesn’t affect you at all.
	3.3 Prévention - Vaccins
HPV vaccine doesn't cause chronic pain, review finds [STAT] The European Medicines Agency began its review in July after families complained that girls who were vaccinated suffered complex regional pain syndrome, or CRPS, a chronic pain that affects limbs. Other families said the vaccines caused postural orthostatic tachycardia syndrome, or POTS, which causes dizziness and fainting.
Review concludes evidence does not support that HPV vaccines cause CRPS or POTS [EMA] The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a detailed scientific review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines.
	3.4 Chimioprévention
First precision medicine trial in cancer prevention identifies molecular-based chemoprevention strategy [MD Anderson Cancer Center] Patients who tested positive for LOH were considered to be at high risk for oral cancer and were randomized to receive either erlotinib or a placebo for one year. The study’s primary endpoint was to determine if fewer patients treated with erlotinib would develop oral cancer, compared to those that received a placebo.
	4.12 Biopsies liquides
Blood test could help improve prostate cancer outcomes [NHS Choices] The study seems to identify a group who are less likely to benefit from treatment, but it does not follow that everyone who isn't in that group will benefit.
	5. Traitements
Patient-Derived Tumour Xenograft Models Encyclopedia [ESMO] They reported in Nature Medicine that their results suggest that PDX clinical trials may represent a more accurate approach than cell line models for assessing the clinical potential of some therapeutic modalities.
Gut microbes give anticancer treatments a boost [Science] Further analysis by Zitvogel and colleagues suggested that certain bacteria in the Bacteroides and Burkholderia genera were responsible for the antitumor effect of the microbiome.
Vitamin C kills tumor cells with hard-to-treat mutation [Science] Cantley hopes to soon start clinical trials that will select cancer patients based on KRAS or BRAF mutations and possibly GLUT1 status.
	5.2 Pharma
Global Analysis Of Metastatic Breast Cancer Landscape Reveals Gaps In Patient Care And Support [Pfizer] First-of-its-kind Global Report Commissioned by Pfizer, Working Collaboratively with the European School of Oncology, Aims to Catalyze a Global Call-to-Action to Improve Metastatic Breast Cancer Outcomes by 2025.
	5.2.3 Pharma - économie
GSK, Gates Foundation help immuno-oncology player to $56M Series A round [FierceBiotech] In immuno-oncology, this allows Atreca to profile the immune responses of the subset of patients who respond best to checkpoint inhibitors and immune activators. By understanding why these people respond particularly well to treatment, Atreca thinks it can design drugs that enable the rest of the patient population to experience such immune responses.
	5.3 Traitements - FDA, EMA,...
European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Previously Treated Advanced Renal Cell Carcinoma [BMS] Overall survival results from CheckMate -025, a landmark Phase 3 study comparing Opdivo versus everolimus in this patient population, serves as basis for application.
	5.4 Traitements - Economie
Medicines for breast cancer: the affordability controversy [Institute of Cancer Policy] “As things stand, I think many of the new molecular targeted agents are not affordable to many European countries, and this is only going to get worse.”
	5.8.1 ASH - Communiqués
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting [ARIAD Pharmaceuticals] A total of six abstracts were accepted at ASH.
Seattle Genetics Announces More Than 20 Presentations at ASH 2015 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Plan and Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs [Seattle Genetics] ADCETRIS Data Featured in 17 Presentations, Including Eight Oral Presentations, Support Goal to Establish ADCETRIS as the Foundation of Therapy for CD30-Expressing Malignancies. Clinical Data for SGN-CD33A (Vadastuximab Talirine) and SGN-CD19A (Denintuzumab Mafodotin) ADC Programs to be Highlighted in Oral Presentations.
Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting [Roche] The abstracts include more than 15 oral presentations across a broad range of molecular targets and combinations, as well as different clinical endpoints that Roche is exploring in various blood diseases and lines of treatment.
Takeda to Present Data from Ixazomib's Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting [Takeda] Additional Key Presentations on Takeda’s Leading Hematology-Oncology Portfolio to Highlight ADCETRIS (brentuximab vedotin) Five Year Overall Survival Data in Relapsed/Refractory Hodgkin Lymphoma and Pipeline Data.
Janssen to Showcase Growing Portfolio with More Than 40 Data Presentations at the 2015 American Society of Hematology (ASH) Annual Meeting [Johnson & Johnson] Oral presentations from five Janssen brands across two therapeutic areas will be presented at the meeting, including ibrutinib, daratumumab, siltuximab, imetelstat and rivaroxaban.
AbbVie's Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers [AbbVie] Notably, data scheduled for presentation include results from studies of venetoclax, an investigational oral B-cell lymphoma-2 (BCL-2) inhibitor, in chronic lymphocytic leukemia (CLL) and other hematological malignancies.
	5.8.4 ASH - CAR T
Juno, Kite, Novartis Yelp 'Oh Merde!' at Collects Off-the-Shelf CAR-T Data [TheStreet] The new data, anecdote or whatever you want to call it, is intriguing because it provides a possible answer to one of the major concerns with cellular cancer therapies: How do you turn transformative science into a viable business?
Gene Editing Credited With Eliminating an Infant's Aggressive Cancer in London [Wall Street Journal] the normal CAR method was ruled out. But would it be possible to use T cells from a healthy donor? For this, the Great Ormond Street doctors, as well as investigators from University College London, turned to Cellectis, a French biotech firm in which Pfizer holds an 8% stake.
Leukaemia success heralds wave of gene-editing therapies [Nature News & Comment] One year-old girl treated as plans to inject DNA-cutting technology directly into patients' bodies take shape.
Gene editing tool used to treat girl's cancer in medical first [STAT] TALENs is one of three genome-editing tools that scientists and companies are racing to test in humans as possible treatments for everything from cancer to cystic fibrosis, sickle cell disease, and Huntington’s disease.
UCART19: First in Man Proof of Concept to be Presented at 2015 ASH Annual Meeting [Cellectis] “Cellectis had, is and will invest significant amounts of energy and creativity to provide cancer patients with an accessible, cost-effective, off-the-shelf allogeneic CAR-T therapies across all geographies."
A Cell Therapy Untested in Humans Saves a Baby With Cancer [NY Times] The development is significant because it indicates that cell therapies, which represent an exciting new front in the battle against cancer, might not have to be customized for each patient, saving time and money.
Baby girl is first in the world to be treated with 'designer immune cells' [The Guardian] “We have only used this treatment on one very strong little girl, and we have to be cautious about claiming this will be a suitable treatment option for all children,” said Waseem Qasim , professor of cell and gene therapy at University College London’s (UCL) Institute of Child Health, and a consultant immunologist at GOSH.
New kind of "designer" immune cells clear baby's leukaemia [Reuters] The gene-edited cell treatment was prepared by scientists at GOSH and University College London (UCL) together with the French biotech firm Cellectis, which is now funding full clinical trials of the therapy due to start next year.
Parents who refused to let baby die of leukaemia change medical history [The Telegraph] “She was sick, and in lots of pain, so we had do something. Doctors explained that even if we could try the treatment there was no guarantee that it would work but we prayed it would.”
	6. Lutte contre les cancers
NCRI cancer conference day 4: the cost of cancer care and the immune system (again) [Cancer Research UK] On the final day of the conference the media picked up on two studies. The first found that across a poll of almost 1,500 people many were unaware of the full purpose of the national cancer screening programmes. The second covered clinical trial results on radiotherapy dosing for men with prostate cancer.
	6.5 Médecines alternatives
Well: Living With Cancer: The Lure of Alternative Remedies [NY Times] Like every cancer patient I know, I have been instructed on the curative powers of green tea, flax seeds, frankincense, blueberries, kale, ginger, mistletoe injections, vitamins C and B17, Reiki masters, shark cartilage, visualization, crystals, healing hands, curcumin and resveratrol, energy release exercises, vegan and macrobiotic and alkalizing diets, colonic body cleansing, coffee enemas, hemp oil and (lest I forget) carrots.
	6.7 DMP, Big Data & applis
Conquer Cancer Foundation of ASCO Receives Additional $1 Million Donation from Susan G. Komen® for Development of CancerLinQ™ [ASCO] The new funding from Komen will support system components and professional expertise to include breast cancer clinical decision support, a patient portal customized for patients with breast cancer, and the development of breast cancer specific guidelines and measures.
	6.8 Communication
Advantage Humans: New Campaign Changes the Conversation [ACS] "Our new campaign, Advantage Humans, marks a turning point in the fundamental way we talk about cancer," said Gary Reedy, CEO, American Cancer Society.